Table 1.
Patient characteristics in women with PCOS before and after metformin treatment
| Metformin treatment | Case 1 | Case 2 | Case 3 | |||
|---|---|---|---|---|---|---|
| Before | After | Before | After | Before | After | |
| Age (years) | 25 | 31 | 32 | |||
| BMI (kg/m2) | 25.8 | 25.1 | 27.2 | 25.0 | 26.3 | 27.1 |
| LH (mIU/ml) | 9.9 | 10.13 | 8.19 | 3.06 | 7.50 | 2.51 |
| FSH (mIU/ml) | 5.12 | 6.25 | 4.73 | 4.48 | 5.62 | 5.52 |
| Free testosterone (pg/ml) | 1.6 | 1.4 | 2.4 | 0.8 | 1.0 | 0.6 |
| DHEA-S (μg/ml) | 128 | 287 | 109 | 129 | 157 | – |
| Estradiol (pg/ml) | 45 | 46 | 42 | 33 | 41 | 44 |
| HOMA-IR | 1.97 | 0.97 | 2.48 | 1.6 | 1.72 | 1.67 |
| Endometrial classification | proliferative phase | proliferative phase | proliferative phase | secretory phase | proliferative phase | proliferative phase |
| Pregnancy outcome | unknown | conception after 8 months from the beginning of metformin treatment | conception after 17 months from the beginning of metformin treatment | |||
PCOS, polycystic ovary syndrome; BMI, body mass index; LH, luteinizing hormone; FSH, follicle stimulating hormone; DHEA-S, dehydroepiandrosterone sulfate; HOMA-IR, homeostasis model assessment of insulin resistance (This cited a part of Table 2 in our previous report [10])